Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUDAFED 12 HOUR vs ADVIL ALLERGY SINUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
Temporary relief of nasal congestion, sinus pressure, sneezing, runny nose, itchy/watery eyes, and headache due to colds or allergies,Fever reduction,Minor aches and pains
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (Cr Cl <30 m L/min); shorter in children (3-4 hours)
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Hepatic metabolism via N-demethylation to active metabolite; primarily excreted unchanged in urine
Ibuprofen: Primarily hepatic via CYP2C9; Pseudoephedrine: Hepatic via N-demethylation and oxidative metabolism; Chlorpheniramine: Hepatic via CYP2D6 and CYP3A4.
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
50-60% bound (primarily to albumin and alpha-1-acid glycoprotein)
Ibuprofen: >99% (albumin); pseudoephedrine: <20% (albumin)
2.6-3.5 L/kg in adults; indicates extensive tissue distribution (higher than total body water)
Ibuprofen: 0.1–0.2 L/kg; pseudoephedrine: 2.5–3.5 L/kg (extensive tissue distribution)
Oral: 90-100% (immediate-release); sustained-release: approximately 95%
Ibuprofen: 80–100% oral; pseudoephedrine: >90% oral
GFR 30-50 m L/min: reduce dose to 60 mg every 12 hours. GFR <30 m L/min: use is contraindicated.
If GFR <30 m L/min: avoid use of ibuprofen component; pseudoephedrine dose interval may need to be increased (every 8-12 hours) due to reduced clearance.
Child-Pugh A: no adjustment. Child-Pugh B or C: consider reducing dose or extending interval due to reduced clearance; specific guidelines not established.
Child-Pugh Class A: no adjustment; Class B: use with caution, maximum ibuprofen dose 1200 mg/day; Class C: contraindicated due to risk of hepatotoxicity and renal impairment.
Children 6-12 years: 60 mg orally every 12 hours; maximum 120 mg/day. Children <6 years: not recommended.
Not recommended for children under 12 years of age; for children ≥12 years: same as adult dose (200 mg ibuprofen/30 mg pseudoephedrine) every 4-6 hours, maximum 6 tablets per day.
Start at lower end of dosing range (60 mg every 12 hours); monitor for CNS stimulation, hypertension, and urinary retention.
Initiate at lowest effective dose (1 tablet every 6-8 hours); monitor renal function and blood pressure due to increased risk of GI bleeding, cardiovascular events, and pseudoephedrine-induced hypertension.
None
No FDA black box warning exists for this combination product. However, NSAIDs like ibuprofen carry a black box warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal, especially with prolonged use or in patients with cardiovascular risk factors.
Cardiovascular effects: hypertension, palpitations, tachycardia,CNS stimulation: insomnia, nervousness, dizziness,Exacerbation of narrow-angle glaucoma,Exacerbation of prostatic hypertrophy/urinary retention,Diabetes mellitus: may increase blood glucose
Cardiovascular risk: NSAIDs increase risk of serious cardiovascular events. Gastrointestinal risk: NSAIDs can cause bleeding, ulceration, and perforation. Hypertension: Pseudoephedrine may elevate blood pressure. Avoid use with MAOIs or within 14 days of stopping. Caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and renal impairment.
Severe hypertension,Coronary artery disease,Concurrent or recent (within 14 days) MAOI therapy,Narrow-angle glaucoma,Urinary retention
Hypersensitivity to any component; Concurrent MAOI therapy; Severe hypertension or coronary artery disease; Active peptic ulcer disease; History of aspirin/NSAID-induced asthma; Pregnancy (especially third trimester); Children under 12 years (per product labeling).
Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase central nervous system stimulation and exacerbate side effects like nervousness and insomnia. High-tyramine foods (aged cheeses, cured meats, fermented products) should be limited in patients taking MAOIs, but no direct interaction with pseudoephedrine alone. Alcohol may increase dizziness and should be avoided.
Avoid alcohol due to increased risk of GI bleeding and liver toxicity. No known food interactions with chlorpheniramine or pseudoephedrine. Taking with food may reduce gastric irritation from ibuprofen.
Category C. First trimester: Possible risk of gastroschisis (limited data). Second and third trimesters: Uterine vasoconstriction, reduced placental perfusion; avoid due to risk of fetal hypoxia, tachycardia, and intrauterine growth restriction. No adequate well-controlled human studies.
First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and necrotizing enterocolitis. Avoid use after 30 weeks gestation.
Pseudoephedrine is excreted into breast milk (M/P ratio approximately 2.0-3.5). Use with caution: may reduce milk production and cause irritability in infants. Highest risk in preterm infants or those with impaired renal function. Avoid if possible; use lowest effective dose if necessary.
Ibuprofen and pseudoephedrine are excreted into breast milk. Ibuprofen has low milk/plasma ratio (0.01-0.07) and is generally considered compatible. Pseudoephedrine may reduce milk production and cause irritability in infants. Use with caution, especially in preterm infants.
No specific dose adjustment recommended, but use is generally avoided in pregnancy. If necessary, use immediate-release formulations at lowest effective dose for shortest duration. Extended-release formulations (e.g., 12-hour) are not recommended due to prolonged systemic exposure. Pharmacokinetic changes in pregnancy (increased volume of distribution, reduced plasma concentrations) may necessitate more frequent dosing, but safety data insufficient; avoid.
No specific dose adjustments recommended for pregnancy; however, use the lowest effective dose for the shortest duration. Avoid in third trimester. Pseudoephedrine dose remains standard; caution in hypertensive disorders.
Pseudoephedrine is a sympathomimetic amine that causes vasoconstriction; avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Extended-release formulation provides 12-hour symptom relief. Use with caution in patients with diabetes, hyperthyroidism, or prostatic hyperplasia. Monitor for nervousness, dizziness, or insomnia. Not recommended for use with MAOIs or within 14 days of stopping MAOIs.
Advil Allergy Sinus contains ibuprofen (NSAID), chlorpheniramine (first-generation antihistamine), and pseudoephedrine (decongestant). Avoid in patients with aspirin/NSAID allergy, severe hypertension, coronary artery disease, or MAOI use. Caution in elderly due to anticholinergic effects. Pseudoephedrine may cause insomnia and anxiety; avoid evening dosing.
Do not crush or chew the tablet; swallow whole with water.,Take with food or milk if stomach upset occurs.,Avoid taking within 4-5 hours of bedtime to prevent insomnia.,Do not exceed one tablet every 12 hours; maximum 2 tablets in 24 hours.,Discontinue and consult doctor if symptoms persist beyond 7 days or are accompanied by fever.,Avoid using other medications containing pseudoephedrine or other decongestants.,Do not use if you have high blood pressure, heart disease, or are taking MAOIs.
Do not take if allergic to aspirin or NSAIDs.,Avoid alcohol to reduce risk of stomach bleeding.,Do not use with other products containing NSAIDs or decongestants.,May cause drowsiness; avoid driving or operating machinery.,Do not take for more than 10 days for pain or 3 days for fever.,Consult a doctor if you have high blood pressure, heart disease, glaucoma, or an enlarged prostate.,Pseudoephedrine may cause difficulty sleeping; take last dose at least 4-6 hours before bedtime.,Take with food or milk to minimize stomach upset.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUDAFED 12 HOUR vs ADVIL ALLERGY SINUS, answered by our medical review team.
SUDAFED 12 HOUR is a Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.. ADVIL ALLERGY SINUS is a NSAID/Decongestant/Antihistamine Combination that works by Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUDAFED 12 HOUR and ADVIL ALLERGY SINUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUDAFED 12 HOUR is: 120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.. The standard adult dose of ADVIL ALLERGY SINUS is: 1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUDAFED 12 HOUR and ADVIL ALLERGY SINUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUDAFED 12 HOUR is classified as Category C. Category C. First trimester: Possible risk of gastroschisis (limited data). Second and third trimesters: Uterine vasoconstriction, reduced placental perfusion; avoid due to risk of. ADVIL ALLERGY SINUS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.